Skip to main content
Top
Published in: Journal of Neuroinflammation 1/2018

Open Access 01-12-2018 | Research

Leucine-rich repeat kinase 2 controls protein kinase A activation state through phosphodiesterase 4

Authors: Isabella Russo, Giulietta Di Benedetto, Alice Kaganovich, Jinhui Ding, Daniela Mercatelli, Michele Morari, Mark R. Cookson, Luigi Bubacco, Elisa Greggio

Published in: Journal of Neuroinflammation | Issue 1/2018

Login to get access

Abstract

Background

Evidence indicates a cross-regulation between two kinases, leucine-rich repeat kinase 2 (LRRK2) and protein kinase A (PKA). In neurons, LRRK2 negatively regulates PKA activity in spiny projecting neurons during synaptogenesis and in response to dopamine D1 receptor activation acting as an A-anchoring kinase protein (AKAP). In microglia cells, we showed that LRRK2 kinase activity negatively regulates PKA, impacting NF-κB p50 signaling and the inflammatory response. Here, we explore the molecular mechanism underlying the functional interaction between LRRK2 and PKA in microglia.

Methods

To understand which step of PKA signaling is modulated by LRRK2, we used a combination of in vitro and ex vivo systems with hyperactive or inactive LRRK2 as well as different readouts of PKA signaling.

Results

We confirmed that LRRK2 kinase activity acts as a negative regulator of PKA activation state in microglia. Specifically, we found that LRRK2 controls PKA by affecting phosphodiesterase 4 (PDE4) activity, modulating cAMP degradation, content, and its dependent signaling. Moreover, we showed that LRRK2 carrying the G2019S pathological mutation downregulates PKA activation causing a reduction of PKA-mediated NF-κB inhibitory signaling, which results, in turn, in increased inflammation in LRRK2 G2019S primary microglia upon α-synuclein pre-formed fibrils priming.

Conclusions

Overall, our findings indicate that LRRK2 kinase activity is a key regulator of PKA signaling and suggest PDE4 as a putative LRRK2 effector in microglia. In addition, our observations suggest that LRRK2 G2019S may favor the transition of microglia toward an overactive state, which could widely contribute to the progression of the pathology in LRRK2-related PD.
Literature
11.
20.
27.
go back to reference Cognet I, de Coignac AB, Magistrelli G, Jeannin P, Aubry J-P, Maisnier-Patin K, et al. Expression of recombinant proteins in a lipid A mutant of Escherichia coli BL21 with a strongly reduced capacity to induce dendritic cell activation and maturation. J Immunol Methods. 2003;272:199–210 Available from: http://www.ncbi.nlm.nih.gov/pubmed/12505724. Cited 23 Aug 2018.CrossRef Cognet I, de Coignac AB, Magistrelli G, Jeannin P, Aubry J-P, Maisnier-Patin K, et al. Expression of recombinant proteins in a lipid A mutant of Escherichia coli BL21 with a strongly reduced capacity to induce dendritic cell activation and maturation. J Immunol Methods. 2003;272:199–210 Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​12505724. Cited 23 Aug 2018.CrossRef
41.
go back to reference Zou Z-Q, Chen J-J, Feng H-F, Cheng Y-F, Wang H-T, Zhou Z-Z, et al. Novel phosphodiesterase 4 inhibitor FCPR03 alleviates lipopolysaccharide-induced neuroinflammation by regulation of the cAMP/PKA/CREB signaling pathway and NF- κ B inhibition. J Pharmacol Exp Ther. 2017;362:67–77 Available from: http://www.ncbi.nlm.nih.gov/pubmed/28450469. Cited 1 Feb 2018.CrossRef Zou Z-Q, Chen J-J, Feng H-F, Cheng Y-F, Wang H-T, Zhou Z-Z, et al. Novel phosphodiesterase 4 inhibitor FCPR03 alleviates lipopolysaccharide-induced neuroinflammation by regulation of the cAMP/PKA/CREB signaling pathway and NF- κ B inhibition. J Pharmacol Exp Ther. 2017;362:67–77 Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​28450469. Cited 1 Feb 2018.CrossRef
43.
go back to reference Daher JPL, Abdelmotilib HA, Hu X, Volpicelli-Daley LA, Moehle MS, Fraser KB, et al. Leucine-rich repeat kinase 2 (LRRK2) pharmacological inhibition abates ??-synuclein gene-induced neurodegeneration. J Biol Chem. 2015;290:19433–44.CrossRef Daher JPL, Abdelmotilib HA, Hu X, Volpicelli-Daley LA, Moehle MS, Fraser KB, et al. Leucine-rich repeat kinase 2 (LRRK2) pharmacological inhibition abates ??-synuclein gene-induced neurodegeneration. J Biol Chem. 2015;290:19433–44.CrossRef
Metadata
Title
Leucine-rich repeat kinase 2 controls protein kinase A activation state through phosphodiesterase 4
Authors
Isabella Russo
Giulietta Di Benedetto
Alice Kaganovich
Jinhui Ding
Daniela Mercatelli
Michele Morari
Mark R. Cookson
Luigi Bubacco
Elisa Greggio
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Journal of Neuroinflammation / Issue 1/2018
Electronic ISSN: 1742-2094
DOI
https://doi.org/10.1186/s12974-018-1337-8

Other articles of this Issue 1/2018

Journal of Neuroinflammation 1/2018 Go to the issue